Study guide
10.2 Thyroid and Adrenal Disorders in the Cardiac Patient
AACN Cardiac Medicine Certification CMC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview and the CMC Test Plan
1.1 CMC Exam Format, Eligibility, Fees & Scoring 1.2 The CMC Test Plan: Four Domains and How to Study Them
2 Chapter 2: Acute Coronary Syndromes and Ischemic Heart Disease
2.1 Pathophysiology & Classification of Acute Coronary Syndromes 2.2 12-Lead ECG Localization & Cardiac Biomarker Trajectories 2.3 Acute Reperfusion Strategies & Nursing Management 2.4 Complications of Acute Myocardial Infarction 2.5 Chronic Coronary Disease, Hyperlipidemia and Lipid-Lowering Therapy
3 Chapter 3: Heart Failure, Cardiomyopathies, Pericardial and Valvular Disease
3.1 Acute Decompensated Heart Failure & Staging 3.2 Acute Cardiogenic Pulmonary Edema 3.3 Dilated, Hypertrophic, and Restrictive Cardiomyopathies 3.4 Acute Pericarditis, Cardiac Tamponade & Constrictive Pericarditis 3.5 Infective Endocarditis, Myocarditis and Rheumatic Heart Disease 3.6 Valvular Heart Disease: Stenosis & Regurgitation 3.7 Syncope: Cardiac Versus Non-Cardiac Causes and Workup
4 Chapter 4: Dysrhythmias, Conduction Disorders and Electrophysiologic Interventions
4.1 Atrial Fibrillation, Atrial Flutter & Supraventricular Tachycardias 4.2 Ventricular Arrhythmias & Cardiac Arrest Management 4.3 Atrioventricular Blocks & Intraventricular Conduction Delays 4.4 Temporary Pacing: Transcutaneous, Transvenous and Epicardial 4.5 Permanent Pacemakers, CRT and Device Troubleshooting 4.6 Implantable and Wearable Cardioverter Defibrillators 4.7 Catheter Ablation and Post-Ablation Nursing Care 4.8 Synchronized Cardioversion and Defibrillation
5 Chapter 5: Vascular Conditions and Vascular Interventions
5.1 Aortic Dissection, Aortic Aneurysms & Hypertensive Crises 5.2 Peripheral Artery Disease & Acute Limb Ischemia 5.3 Acute Venous Thrombosis, DVT and VTE Prophylaxis 5.4 Peripheral and Carotid Angiography and Interventions 5.5 Endovascular Aortic Repair: EVAR and TEVAR 5.6 Catheter-Directed Thrombolysis and Post-Intervention Vascular Complications
6 Chapter 6: Shock States and Mechanical Circulatory Support
6.1 Cardiogenic Shock Pathophysiology, Hemodynamics & Etiologies 6.2 Non-Cardiogenic Shock: Hypovolemic, Distributive and Obstructive 6.3 Multisystem Organ Dysfunction Syndrome 6.4 Intra-Aortic Balloon Pump Therapy & Waveform Optimization 6.5 Percutaneous & Surgical Mechanical Circulatory Support: Impella, VA-ECMO, LVAD
7 Chapter 7: Cardiac Procedures and Structural Heart Interventions
7.1 Diagnostic Cardiac Catheterization & Coronary Angiography Interpretation 7.2 Percutaneous Coronary Intervention: Stents, No-Reflow and Post-PCI Care 7.3 Structural Heart Interventions: TAVR, MitraClip, Pericardiocentesis 7.4 Post-Cardiac Surgery Management (>48 Hours) & Late Complications
8 Chapter 8: Cardiovascular Pharmacology
8.1 Inotropes, Vasopressors & Inodilators 8.2 Vasodilators & Antianginal Agents 8.3 Antiarrhythmic Agents: Vaughan Williams Classes I-IV 8.4 Anticoagulants, Antiplatelets, Thrombolytics & Reversal Agents 8.5 Diuretics and Decongestion Strategies 8.6 Guideline-Directed Medical Therapy for Heart Failure
9 Chapter 9: Non-Cardiovascular Conditions: Pulmonary
9.1 Acute Pulmonary Embolism 9.2 Acute Respiratory Failure and ARDS 9.3 Pleural Space Abnormalities: Pneumothorax, Effusion and Hemothorax 9.4 Pulmonary Hypertension and Right Ventricular Failure 9.5 Sleep-Disordered Breathing in Cardiac Patients
10 Chapter 10: Non-Cardiovascular Conditions: Endocrine, Renal, Hematologic, Neurologic and Behavioral
10.1 Diabetes Mellitus and Glycemic Control in Cardiac Care 10.2 Thyroid and Adrenal Disorders in the Cardiac Patient 10.3 Metabolic Syndrome and Cardiometabolic Risk 10.4 Coagulopathies: Heparin-Induced Thrombocytopenia, DIC and Bleeding Disorders 10.5 Anemia and Transfusion Management in Cardiac Patients 10.6 Acute Ischemic and Hemorrhagic Stroke in the Cardiac Patient 10.7 Acute Kidney Injury and Contrast-Associated Nephropathy 10.8 Chronic Kidney Disease and the Dialysis-Dependent Cardiac Patient 10.9 Electrolyte Imbalances and Dysrhythmia Risk 10.10 Substance Use, Withdrawal and Cardiac Effects 10.11 Non-Cardiac Chest Pain: Differential and Triage 10.12 Non-Cardiovascular Multisystem Complications in Cardiac Patients
11 Chapter 11: Monitoring and Diagnostics
11.1 Pulmonary Artery Catheterization & Hemodynamic Waveform Interpretation 11.2 Arterial Line Monitoring, Continuous Cardiac Output & ScvO2 11.3 Echocardiography, Cardiac MRI & Non-Invasive Cardiac Imaging 11.4 Stress Testing and Myocardial Perfusion Imaging 11.5 Remote Cardiovascular Monitoring and Ambulatory Rhythm Devices 11.6 Laboratory Testing in Cardiac Care 11.7 Arterial Blood Gases and Acid-Base Interpretation 11.8 Pulse Oximetry, Capnography and Chest Radiography
12 Chapter 12: Respiratory, Renal and Multisystem Therapeutic Interventions
12.1 Non-Invasive Ventilation in Cardiac Patients 12.2 Invasive Mechanical Ventilation and Heart-Lung Interactions 12.3 Renal Replacement Therapy: Hemodialysis, CRRT, SCUF and Ultrafiltration 12.4 Targeted Temperature Management After Cardiac Arrest 12.5 Palliative and End-of-Life Care in Advanced Cardiac Disease
10.2 Thyroid and Adrenal Disorders in the Cardiac Patient
Key Takeaways Explain This Topic AI
Every patient with new-onset atrial fibrillation needs a TSH; thyrotoxic AF is often rate-control refractory until the patient is euthyroid.
Thyroid storm is treated in sequence - beta blocker, then thionamide, then iodine at least one hour after the thionamide, plus hydrocortisone - because iodine given first fuels new hormone synthesis.
Amiodarone is 37% iodine by weight with a 40-58 day half-life; check TSH and free T4 at baseline, 3 months, then every 6 months. Type 1 thyrotoxicosis (vascular, abnormal gland) gets a thionamide; type 2 (avascular, normal gland) gets a glucocorticoid.
Adrenal crisis presents as vasopressor-refractory distributive shock with hyponatremia, hyperkalemia, hypoglycemia and eosinophilia; give hydrocortisone 100 mg IV then 50 mg q6h without waiting for cortisol results.
In pheochromocytoma, alpha blockade must precede beta blockade for 10-14 days; a beta blocker first leaves unopposed alpha vasoconstriction and can precipitate hypertensive crisis and pulmonary edema.
Last updated: August 2026
Thyroid Hormone Is a Cardiovascular Drug
Thyroid hormone acts directly on the myocardium and vasculature: it increases beta-adrenergic receptor density and post-receptor signaling, increases the expression of the fast myosin heavy chain and the sarcoplasmic reticulum calcium ATPase (SERCA2a), raises heart rate and contractility, shortens diastolic relaxation time, and relaxes vascular smooth muscle so that systemic vascular resistance (SVR) falls. That combination — high output, low resistance — explains almost every cardiac finding in thyroid disease.
- Parameter Hyperthyroidism Hypothyroidism
- Heart rate Sinus tachycardia, often persists in sleep Sinus bradycardia
Rhythm Atrial fibrillation in 10-15%, rate often hard to control Bradyarrhythmias, prolonged QT with torsades risk
Contractility / output Increased; high-output state, cardiac index often above 4 Decreased; low cardiac output, reduced stroke volume
SVR Decreased; wide pulse pressure, systolic hypertension Increased; diastolic hypertension, narrow pulse pressure
Blood volume Increased Decreased
ECG Sinus tachycardia, AF, occasionally ST-T changes Low voltage, flat or inverted T waves, prolonged QT, first-degree AV block
Other cardiac findings Angina exacerbation, high-output heart failure, mitral valve prolapse Pericardial effusion, elevated CK, elevated LDL and total cholesterol, diastolic dysfunction
Hyperthyroidism, atrial fibrillation and thyroid storm
Every patient with new-onset atrial fibrillation needs a thyroid-stimulating hormone (TSH) level. The 2023 ACC/AHA/ACCP/HRS atrial fibrillation guideline includes thyroid function in the initial evaluation. Thyrotoxic AF is often refractory to standard rate control until the patient is rendered euthyroid, and a substantial proportion converts spontaneously once thyroid function normalizes. Anticoagulation is decided by CHA2DS2-VASc, not by the presence of hyperthyroidism alone.
Thyroid storm is decompensated thyrotoxicosis with organ dysfunction. Precipitants that a cardiac nurse will actually encounter: surgery, infection, myocardial infarction, iodinated contrast, amiodarone, abrupt withdrawal of antithyroid drugs, DKA, and trauma. The Burch-Wartofsky point scale (fever, central nervous system effects, gastrointestinal-hepatic dysfunction, tachycardia, heart failure, atrial fibrillation, and a precipitant) supports the diagnosis at 45 points or more. Cardiovascular presentation is temperature above 38.5 to 41 degrees Celsius, a heart rate disproportionate to the fever, AF with rapid ventricular response, high-output or frankly decompensated heart failure, agitated delirium, and vomiting or diarrhea driving volume loss. Mortality is 10 to 30 percent.
The management sequence matters and is heavily tested:
Beta blockade first for the adrenergic storm. Propranolol 60 to 80 mg orally every 4 to 6 hours, or 0.5 to 1 mg IV slowly, additionally blocks peripheral T4-to-T3 conversion. In the ICU an esmolol infusion is preferable because it is titratable and can be turned off in seconds.
Thionamide to stop new hormone synthesis. Propylthiouracil (PTU) 500 to 1,000 mg load then 250 mg every 4 hours is preferred in storm because it also blocks peripheral conversion; methimazole 20 mg every 4 to 6 hours is an alternative.
Iodine at least one hour after the thionamide. Saturated solution of potassium iodide 5 drops every 6 hours or Lugol solution blocks hormone release (Wolff-Chaikoff effect). Giving iodine first supplies substrate to an unblocked gland and can worsen thyrotoxicosis (Jod-Basedow phenomenon). This one-hour rule is a classic exam item.
Corticosteroid — hydrocortisone 300 mg IV then 100 mg every 8 hours — blocks T4-to-T3 conversion and covers the relative adrenal insufficiency of storm.
Cooling with acetaminophen , not aspirin: salicylates displace thyroid hormone from thyroid-binding globulin and raise free hormone levels.
The nursing caution: in storm with high-output or decompensated heart failure , aggressive beta blockade can remove the tachycardia that is sustaining cardiac output and precipitate cardiovascular collapse. Use short-acting esmolol, titrate against blood pressure, mental status, urine output and, when available, cardiac output or mixed venous saturation; be prepared to stop the infusion and support with inotropes.
Hypothyroidism and myxedema coma
Overt hypothyroidism produces bradycardia, reduced contractility, low cardiac output, increased SVR with diastolic hypertension, a narrow pulse pressure, pericardial effusion (usually slowly accumulating and rarely tamponading), atherogenic dyslipidemia, elevated creatine kinase, and QT prolongation with a real risk of torsades de pointes.
Myxedema coma is the decompensated form: hypothermia without shivering, hypoventilation with carbon dioxide retention, hyponatremia, hypoglycemia, bradycardia, hypotension, and depressed mentation, usually precipitated by cold exposure, infection, sedatives, or an acute cardiac event. Management principles for the CMC exam:
Give hydrocortisone 100 mg IV before thyroid hormone whenever coexisting adrenal insufficiency cannot be excluded. Thyroid replacement accelerates cortisol clearance and can precipitate adrenal crisis in a patient with limited reserve.
Levothyroxine 200 to 400 mcg IV load, then 50 to 100 mcg daily, with lower loading doses in older patients and those with coronary disease because rapid repletion increases myocardial oxygen demand and can trigger ischemia or arrhythmia. Liothyronine (T3) may be added in refractory cases.
Passive rewarming with blankets. Active external rewarming causes peripheral vasodilation and can precipitate hypotension in a volume-depleted, low-output patient.
Treat hyponatremia with free-water restriction, support ventilation, correct hypoglycemia, and monitor continuously for bradyarrhythmia and QT-related ventricular arrhythmia.
Amiodarone and the thyroid
Amiodarone is 37 percent iodine by weight. A single 200 mg tablet liberates roughly 7 mg of free iodine daily against a recommended daily allowance of 150 micrograms — a 40- to 50-fold iodine load. Its half-life of 40 to 58 days means thyroid effects persist for months after the drug is stopped.
Amiodarone-induced hypothyroidism (AIH) is the more common problem in iodine-sufficient countries such as the United States, occurring in up to 20 percent of patients. It is treated with levothyroxine, and amiodarone can usually be continued if it is controlling a serious arrhythmia.
Amiodarone-induced thyrotoxicosis (AIT) type 1 occurs in an abnormal gland (nodular goiter or latent Graves disease). The iodine load fuels excess synthesis. Color-flow Doppler shows increased vascularity. Treatment is a thionamide , sometimes with potassium perchlorate.
AIT type 2 is a destructive thyroiditis in a structurally normal gland releasing preformed hormone. Doppler shows low or absent vascularity. Treatment is a glucocorticoid , typically prednisone 40 to 60 mg daily.
Mixed and indeterminate forms are common and are treated with both. Thyroidectomy is an option in refractory AIT with hemodynamic compromise.
Monitoring: TSH and free T4 at baseline, at 3 months, and then every 6 months for the duration of therapy and for up to a year after discontinuation. Amiodarone surveillance also includes liver enzymes, a baseline chest radiograph and pulmonary function with diffusing capacity, and periodic ophthalmologic examination.
Interpretation caveat: amiodarone inhibits deiodinase, so in the first few months a transient TSH rise with a normal or slightly high free T4 and a low T3 is an expected drug effect, not disease. Judge on the trend and the free T4, not on a single TSH.
Euthyroid sick syndrome
Non-thyroidal illness syndrome appears in acute MI, cardiogenic shock, after cardiac surgery, and in advanced heart failure. The pattern is a low T3 first (impaired 5-prime-deiodinase activity), then a falling T4 in severe illness, with a normal or low TSH and an elevated reverse T3. It reflects an adaptive reduction in metabolic rate. Treating it does not improve outcomes and may cause harm. Do not order routine thyroid panels in the acutely ill cardiac patient unless thyroid disease is genuinely suspected; if a panel was drawn and is abnormal, recheck 6 to 8 weeks after recovery. During recovery the TSH may rebound above normal, which is not new hypothyroidism.
- Adrenal Disorders in the Cardiac Patient
- Primary versus secondary adrenal insufficiency
- Feature Primary (Addison disease) Secondary (pituitary or exogenous steroid)
- Defect Destruction of the adrenal cortex Deficient ACTH; most often chronic exogenous glucocorticoid
- Cortisol Low Low
- Aldosterone Low (renin-angiotensin axis intact but gland cannot respond) Preserved
- ACTH High Low or inappropriately normal
- Sodium / potassium Hyponatremia and hyperkalemia Hyponatremia possible; potassium usually normal
- Skin Hyperpigmentation Normal or pale
- Volume status Marked depletion Less depleted
- Adrenal crisis: vasopressor-refractory distributive shock
This is the single highest-yield adrenal item on the CMC exam. Suspect adrenal crisis in any patient with distributive shock that will not respond to fluid and escalating norepinephrine. Supporting features are hyponatremia, hyperkalemia, hypoglycemia, eosinophilia, a mildly elevated urea-to-creatinine ratio, unexplained fever, abdominal pain and vomiting, and a low or low-normal cortisol in a physiologically stressed patient. The at-risk populations in a cardiac unit are patients on chronic corticosteroids (more than 5 mg of prednisone equivalent daily for more than three weeks) whose steroid was abruptly held on admission or omitted while NPO, patients with adrenal hemorrhage on anticoagulation or in HIT, and patients with known hypopituitarism.
Diagnosis: a random cortisol below 5 mcg/dL during shock is strongly suggestive, because an appropriately stressed adrenal axis should produce a value above 18 mcg/dL. Confirmation is the cosyntropin stimulation test — 250 mcg IV with cortisol measured at baseline and 30 and 60 minutes; a peak below 18 mcg/dL indicates insufficiency.
Never delay steroids for the test. Draw a random cortisol and treat. If testing must proceed after treatment has begun, dexamethasone 4 mg IV provides glucocorticoid activity without interfering with the cortisol immunoassay, whereas hydrocortisone cross-reacts.
Treatment: hydrocortisone 100 mg IV bolus, then 50 mg every 6 hours or 200 mg per 24 hours as a continuous infusion , plus aggressive isotonic crystalloid with dextrose for hypoglycemia. At doses of 50 mg per day or more, hydrocortisone provides enough mineralocorticoid effect that fludrocortisone is unnecessary. The clinical response is often dramatic: vasopressor requirements fall within hours, and that response is itself diagnostic support.
Stress dosing around procedures: a patient on chronic replacement usually needs only the usual dose or 25 mg of hydrocortisone for a diagnostic cardiac catheterization, 50 to 75 mg per day for moderate procedures, and 100 to 150 mg per day for 2 to 3 days with a taper for major surgery. The nursing responsibility is to notice the home steroid on the medication reconciliation and ensure it is not silently dropped when the patient is NPO.
Critical-illness-related corticosteroid insufficiency (CIRCI) describes inadequate cortisol activity relative to the severity of illness. Surviving Sepsis Campaign 2021 suggests IV hydrocortisone 200 mg per day for adults with septic shock and an ongoing vasopressor requirement (for example, norepinephrine at 0.25 mcg/kg/min or more for at least 4 hours after initiation). Monitor for hyperglycemia, hypernatremia, and rebound hypotension when it is withdrawn abruptly.
Pheochromocytoma
A catecholamine-secreting tumor presenting with paroxysmal hypertension, headache, palpitations and diaphoresis — the classic triad — plus pallor, anxiety, and orthostatic hypotension between spells. It can mimic ACS with chest pain and troponin elevation, or produce a takotsubo-like catecholamine cardiomyopathy with normal coronary arteries. Screening is plasma free metanephrines or 24-hour urinary fractionated metanephrines.
The absolute rule: alpha blockade must precede beta blockade. Phenoxybenzamine 10 mg twice daily titrated upward, or doxazosin, for 10 to 14 days with liberal salt and fluid intake to re-expand the contracted intravascular volume; a beta blocker is added only afterward for reflex tachycardia. Giving a beta blocker first removes beta-2-mediated vasodilation and leaves unopposed alpha vasoconstriction , producing a hypertensive crisis, pulmonary edema, and possible cardiovascular collapse. During an intraoperative or spontaneous crisis, use phentolamine, nicardipine, clevidipine, or nitroprusside for pressure and esmolol for rate. After tumor resection, expect abrupt hypotension from catecholamine withdrawal and residual alpha blockade — have volume and vasopressors at the bedside.
Cortisol and aldosterone excess as causes of resistant hypertension
Cushing syndrome produces hypertension, hypokalemia, glucose intolerance, central obesity, left ventricular hypertrophy, and a hypercoagulable state with elevated venous thromboembolism risk. Primary hyperaldosteronism is the most common secondary cause of resistant hypertension, found in 5 to 20 percent of resistant hypertensives, and classically presents as hypertension with spontaneous or diuretic-provoked hypokalemia and metabolic alkalosis (though many patients are normokalemic). Screen with an aldosterone-to-renin ratio, holding interfering agents where feasible. Treatment is a mineralocorticoid receptor antagonist — spironolactone or eplerenone — or adrenalectomy for a unilateral adenoma. The cardiac relevance is direct: aldosterone excess drives myocardial and vascular fibrosis, left ventricular hypertrophy, atrial fibrillation, and stroke independently of the blood pressure it causes.